Stratagene Highlights Results of FDA's MicroArray Quality Control Project; Stratagene's Universal Reference RNA Proves Valuable
September 12 2006 - 6:30AM
Business Wire
Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer and
marketer of specialized life science research and diagnostic
products, today highlighted the U.S. Food and Drug Administration's
(FDA) publication of results from its MicroArray Quality Control
(MAQC) project. As part of the FDA's Critical Path Initiative, the
MAQC project aimed to develop standards and quality measures for
the microarray community, so that microarrays, as a core technology
of pharmacogenomics and toxicogenomics, could successfully and
reliably be used in clinical practice and regulatory
decision-making. As a result, the MAQC project will help improve
microarray technology and foster its proper applications in the
discovery, development and review of FDA regulated products. "We
are proud to have been a part of this collaboration that brought
together a broad range of academic, governmental, and commercial
organizations, all with the future of microarray technology in
mind," said Joseph A. Sorge, MD, President and CEO of Stratagene.
"Stratagene's Universal Reference RNA was one of two high-quality
reference standards selected as part of the MAQC project. These
reference RNAs allow laboratories with many different microarray
platforms to compare and share data in the global microarray
community." The project involved six FDA Centers, major providers
of microarray platforms and RNA samples, the U.S Environmental
Protection Agency, the National Institute of Standards and
Technology, academic laboratories, and other stakeholders. By
providing the public with large reference datasets along with
readily accessible reference RNA samples, the MAQC project aimed to
establish quality control metrics and thresholds for objectively
assessing the performance achievable by various microarray
platforms and evaluating the advantages and disadvantages of
various data analysis methods. For more information about the MAQC
project, visit
http://www.fda.gov/nctr/science/centers/toxicoinformatics/maqc/
index.htm. (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove
the extra space if one exists.) For more information about
Stratagene's Universal Reference RNAs, visit
http://www.stratagene.com/microarrays. About Stratagene Corporation
Stratagene is a developer, marketer and manufacturer of specialized
life science research and diagnostic products. The Company's life
science research unit supports advances in science by inventing,
manufacturing and distributing products that simplify, accelerate
and improve research. These products are used throughout the
academic, industrial and government research sectors in fields
spanning molecular biology, genomics, proteomics, drug discovery
and toxicology. The Company's diagnostic unit develops and
manufactures products for urinalysis, and high quality automated
instrument and reagent systems that use blood samples to test for
more than 1,000 different allergies and autoimmune disorders. In
addition, by combining its expertise in diagnostics and molecular
biology, as well as its experience with FDA regulatory procedures,
the Company is pursuing opportunities to expand its product
portfolio to include molecular diagnostic kits and instrumentation.
More information is available at www.stratagene.com.
Stratagene (NASDAQ:STGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Stratagene (NASDAQ:STGN)
Historical Stock Chart
From Oct 2023 to Oct 2024